192results about "Invertebrate antigen ingredients" patented technology

Disclosed are compositions and methods that provide synthetic nanocarriers that comprise hydrophobic polyester carrier material and rapamycin that is in a stable, super-saturated amount. In some embodiments, the synthetic nanocarriers are also initially sterile filterable. In other embodiments, the rapamycin is present in the synthetic nanocarrier compositions in an amount that is less than 50 weight % rapamycin / hydrophobic polyester carrier material in the composition.

Preparations which elicit an immune response to hookworm antigens and which may be utilized as hookworm vaccines are provided. In addition, a method of increasing the effectiveness of vaccinations against infectious diseases in patients infected with hookworm is provided. The method involves chemically treating the hookworm infestation prior to administering the vaccine.

This invention relates to methods of using a Listeria vaccine vector to induce a Th1 immune response in subjects having persistent Th2 immune response profiles.

The present disclosure provides a compound of formula (I) or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof. Compositions comprising the aforementioned compounds and the use for delivering therapeutic or prophylactic agents are also provided.

The instant invention provides various formulations comprising combinations of immunostimulating oligonucleotides, polycationic carriers, sterols, saponins, quaternary amines, TLR-3 agonists, glycolipids, and MPL-A or analogs thereof in oil emulsions, use thereof in preparations of immunogenic compositions and vaccines, and use thereof in the treatment of animals.

The invention relates to labelling agents containing a compound with two labelled molecules and a vinyl sulphone group. The invention also relates to the compounds, the method for obtaining these and the uses thereof in the marking of biomolecules and, more specifically, proteins.

The present invention is a multivalent vaccine for immunizing an animal against filariasis. In some embodiments, the antigens of the multivalent vaccine are protein-based, DNA-based, or a combination thereof.

The present invention relates to nucleotide sequences encoding Cooperia antigens, as well as to recombinant DNA molecules containing such nucleotide sequences and host cells expressing these nucleotide sequences. The invention further relates to Cooperia proteins, to methods for the production of the proteins, nucleotide sequences, recombinant DNA molecules and hosts. Furthermore, the invention relates to vaccines which induce protective immunity against infection by parasitic nematodes such as species of the genus Cooperia and to methods for preparing such a vaccine.

The invention discloses a coding gene of haemaphysalis qinghaiensis aquaporins (AQPs) and an application of the coding gene. The coding gene of the AQPs can be used for preparing novel anti-tick medicines and anti-tick vaccines. A sequence of the coding gene of the AQPs is shown as SEQ ID NO:1. The invention also provides specific primers cloned by the coding gene of the AQPs, wherein sequences ofthe specific primers are shown as SEQ ID NO:2 and SEQ ID NO:3; the invention also provides a method for cloning the coding gene of the AQPs, and the cloned gene product can be also applied to in-vitro recombinant protein expression and antibody preparation; and an obtained antibody can be used for preparing the novel anti-tick medicines and the anti-tick vaccines. The invention has important theoretical significance an potential application value on prevention and control of ticks. The coding gene of the haemaphysalis qinghaiensis aquaporins (AQPs) and the cloning method of the coding gene provided by the invention are applicable to systematic researches of subtype, varieties, expression distributin, protein structures, biological functions and the like of the AQPs.

A composition for and a method of eliciting in a vertebrate a protective immune response against an eukaryotic parasite are disclosed. The method includes administering to the vertebrate a composition having a carrier group coupled to an oligosaccharide obtained from a lipoglycan found on the surface of an eukaryote. The composition is administered in an amount sufficient to elicit a protective immune response against the parasite.

The present invention provides methods of selecting and uses of anti-arthropod vector vaccines to prevent Leishmaniasis. The present invention also provides compositions for vaccines to prevent Leishmaniasis.

The present invention relates to a protein having antigenic activity against liver flukes, and more particularly, to an antigenic protein having enhanced sensitivity and specificity for the diagnosis and treatment of the liver flukes by producing proteins having antigenic activity against the liver flukes. The antigenic protein includes sequences selected from all or parts of amino acid sequences which are selected from the group consisting of SEQ ID Nos. 1 to 4 of the present invention.

The present invention relates to compositions comprising peptides for preventing or treating allergy to house dust mites, and in particular to optimal combinations of peptides for preventing or treating said allergy.

The present invention relates to the use of a protein termed 64p in the production of vaccines for protecting animals against the bite of blood-sucking ectoparasites and against the transmission of viruses, bacteria and other pathogens by such ectoparasites.

The present invention relates to the use of a peptide of P0 ribosomal protein in the manufacture of a vaccine composition to control of ectoparasite infestations and therefore the transmission of their associated pathogens. This peptide is located between 267 and 301 amino acids of the P0 protein, and can be obtained by recombinant means or by chemical synthesis. This peptide can be fused to a carrier protein or peptide, or an immuno-carrier and be included in an oily formulation. The formulations comprising the peptide vaccine confer protection against ticks and ectoparasites known as “sea lice” without generating autoimmunity in the host organism. Among these ticks may be mentioned species as Rhipicephalus microplus, Rhipicephalus sanguineus and Ixodes scapularis, and between sea lice are those of the Caligus and Lepeophtheirus genera.

A nucleic acid molecule or construct alone or with a promoter suitable for expression control is contemplated that codes for a haemocyanin, a haemocyanin domain or a fragment thereof with the immunological properties of at least one domain of haemocyanin, and comprises at least one intron sequence, as well as haemocyanin fusion proteins. The construct furthermore can comprise a nucleic acid sequence that codes for an antigen. Host cells are also contemplated that contain the nucleic acid molecule or construct and a recombinant expression product thereof. The invention furthermore relates to a pharmaceutical composition that comprises the expression product and antibodies obtainable by immunization of an animal therewith, as well as the use the antibodies in screening methods for the identification of tumors.

The invention relates to a design and preparation method and an application of an echinococcus multilocularis subunit vaccine LTB-Emy162. The active component of the echinococcus multilocularis subunit vaccine LTB-Emy162 is a polypeptide, which is mainly composed of an echinococcus multilocularis antigen protein Emy162 amino acid sequence and a mucosal immunoadjuvant E. coli heat-labile enterotoxin B subunit (LTB) amino acid sequence. In the invention, the gene sequence of the echinococcus multilocularis subunit vaccine LTB-Emy162 is synthesized through gene synthesis technology, the gene sequence is then linked to an expression vector through dual enzyme-cut, the expression vector then is converted into Arctic Express to perform expression of fusion protein, after purification of the protein, the echinococcus multilocularis subunit vaccine LTB-Emy162 is produced. The echinococcus multilocularis subunit vaccine can induce body to generate T-cell and B-cell immunologic response of the echinococcus multilocularis and humoral immune response of a high-titer specific antibody, and can be applied in prevention and therapy of echinococcus multilocularis infection related diseases.

The present invention relates to treating and preventing symptoms of an allergy, asthma, an autoimmune disease, and transplant rejection using a combination vaccine containing a vaccine facilitator comprising a Na / K pump inhibitor, an antigen and a DNA encoding the antigen.

The present invention relates to a polypeptide comprising the amino acid sequence as shown in SEQ ID NO:9 or 7. The invention further pertains to nucleic acids encoding the polypeptide, pharmaceutical compositions and vaccines.

The invention relates to a design, preparing method and applications of an echinococcus multilocularis multi-epitope vaccine LTB-AE. An active component of the multi-epitope vaccine LTB-AE is a polypeptide. The polypeptide mainly comprises an echinococcus multilocularis multi-epitope peptide AE, and a mucosal immune adjuvant that is an escherichia coli heat-labile enterotoxin B subunit (LTB). A gene sequence of the multi-epitope vaccine LTB-AE is synthesized mainly by a gene synthesis technique, and is connected to an expression vector through double digestion, then the expression vector is converted into arctic express to perform expression of a fusion protein, and after the protein is purified, the multi-epitope vaccine LTB-AE is obtained. The multi-epitope vaccine can induce a body to generate immune responses and high-titer specific antibody humoral immune responses to echinococcus multilocularis T cells and B cells, and can be used for preventing and treating echinococcus multilocularis infection related disease.

The invention discloses an attenuated live vaccine for preventing toxoplasma gondii infection and application of the attenuated live vaccine. The attenuated live vaccine is tachyzoite suspension, prepared by taking PBS as a solvent, of a toxoplasma gondii attenuated stain RH: delta gra17 delta npt 1. Toxoplasma gondii double gene knockout is conducted, the immune dosage form of the attenuated livevaccine is determined, the immune vaccination program and dosage of the attenuated live vaccine are verified, it is found that the attenuated live vaccine has a good immune protection effect on toxoplasma gondii acute infection, chronic infection and congenital infection, and toxoplasmosis can be effectively prevented.

The invention relates to an injectable composition for rapid and sustained delivery of a biologically active agent and to uses of the injectable composition in the treatment or prevention of a condition in a subject. The injectable composition comprises a water-in-oil emulsion having an aqueous phase dispersed in an oil phase. The aqueous phase comprises a plurality of hydrogel particles and an aqueous liquid and a biologically active agent is contained in the hydrogel particles and in the aqueous liquid.

Compositions of either the aquaporin protein from the cattle tick, Rhipicephalus microplus, or a nucleic acid construct incorporating a nucleic acid sequence encoding this aquaporin protein, are effective for eliciting a protective immune response against other tick species in non-bovine animals. The R. microplus aquaporin protein is antigenic and can be administered as a protein vaccine, or in the alternative, the nucleic acid construct can be utilized as a DNA vaccine. Induction of the immune response significantly reduces or eliminates the infestation of treated, non-bovine animals with ticks other than the cattle tick, particularly the brown dog tick, Rhipicephalus sanguineus. Moreover, as ticks are vectors of a variety of pathogenic agents, the reduction in the incidence of tick infestation afforded by the vaccines may concurrently reduce the incidence of diseases caused by these pathogenic agents in susceptible animals.

The invention provides a novel fasciola hepatica multi-epitope vaccine. An active ingredient of the novel fasciola hepatica multi-epitope vaccine is a polypeptide. The polypeptide is mainly formed by fasciola hepatica sphingolipid activated mucin-like protein-2 Th, a multicopy body of B-cell epitope and a mucosal immunologic adjuvant cholera toxin B subunit. An artificial gene is mainly synthesized through the gene synthesis technology and comprises Th of sphingolipid activated mucin-like protein-2 and a gene sequence of the multicopy body of the B-cell epitope, then the artificial gene is coupled with the gene sequence of the cholera toxin B subunit, and a fusion gene is formed. An escherichia coli prokaryotic expression system is utilized for expressing the fusion gene, and the fasciola hepatica multi-epitope vaccine is obtained after protein purification. The fasciola hepatica multi-epitope vaccine can induce an organism to generate sphingolipid activated protein T cell immune responses and high-titer specific antibody humoral immune responses, and can be used for preventing and treating fasciola hepatica infection related diseases.